Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study

Peltola, Jukka; Peltola, Maria; Auvinen, Anssi; Keränen, Tapani; Liimatainen, Suvi; Kharazmi, Elham; Fallah, Mahdi

doi:10.1111/j.1600-0404.2007.00956.x

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the end of the 12‐month follow up, 77% of patients were still taking LEV (4). Other open‐label retrospective studies showed similar results concerning the retention on LEV in clinical practice (5, 10–14).…”

Section: Discussionsupporting

confidence: 60%

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up

Kuba

Novotná

Brázdil

et al. 2010

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 60%

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up

Kuba

Novotná

Brázdil

et al. 2010

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…15 Another study showed that when no specific syndrome was identified, there was a greater likelihood of response to levetiracetam in patients with refractory epilepsy compared with those with temporal lobe epilepsy diagnoses. 16 There may be synergistic mechanisms and interactions responsible for the higher effectiveness seen with some AEDs, as have been reported previously for lamotrigine and valproate 17 and for lamotrigine and levetiracetam. 15 The identification of potential predictors of AED response and effectiveness no doubt warrants further study in older adults.…”

Section: Commentmentioning

confidence: 82%

Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy

Arif

Buchsbaum²,

Pierro³

et al. 2010

Arch Neurol

110

View full text Add to dashboard Cite

Patients: Four hundred seventeen outpatients 55 years and older newly taking any of the 10 most commonly prescribed AEDs between 2000 and 2005.Main Outcome Measure: The percentage of patients who remained taking the AED for 12 or more months (12-month "retention"). We also measured efficacy (12month seizure freedom) and adverse effects leading to dose change. Retention and seizure-freedom rates were analyzed by pairwise comparisons using 2 for the overall group and patients with refractory and nonrefractory disease as well as patients newly taking their first AED. Results:The 10 AEDs newly taken by 10 or more patients were analyzed. There were no significant non-AED predictors of retention. Without controlling for se-verity, lamotrigine had the highest 12-month retention rate (79%), significantly higher than carbamazepine (48%), gabapentin (59%), oxcarbazepine (24%), phenytoin (59%), and topiramate (56%). The retention rate for levetiracetam (73%) was second highest and significantly higher than carbamazepine and oxcarbazepine. Oxcarbazepine had the lowest retention rate, significantly lower than all other AEDs. Lamotrigine had the highest 12-month seizure-freedom rate (54%), followed by levetiracetam (43%). When stratified into patients with nonrefractory and refractory disease, relative rates of seizure freedom and retention remained comparable with the overall group. Imbalance, drowsiness, and gastrointestinal symptoms were the most common intolerable adverse effects. Conclusion:In this study of older adults with epilepsy, lamotrigine was the most effective AED as measured by 12-month retention and seizure freedom, with levetiracetam a close second. Oxcarbazepine was consistently less effective than most other AEDs.

show abstract

“…Generalized seizures, drug-resistant seizures and controllable seizures can all cause damage to different lobes of the brain (29)(30)(31). Temporal lobe epilepsy (TLE) is associated with impairment in alertness, impaired memory, executive function and sleepwake disorders (32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

New dimension of epilepsy complications: A literature systematic review of visual and retinal disorders

Negahi,

Sattarzadeh,

Zarei

2023

Preprint

View full text Add to dashboard Cite

Background: Epilepsy usually causes irreparable brain damage with its convulsive attacks, depending on whether it is localized or general, damage to the brain nerves is not far away. Aim: This systematic review, we examined the effect of epilepsy on vision complications. Method: This article was written according to PRISMA criteria from January 2018 to January 2022. These articles were selected from PubMed, Scopus and Google scholar (for results follow-up) databases and 98 articles were studied and 11 of them were used in this article. The principle of non-bias was respected and the results were reviewed at the Cochrane Center. Mesh base Keywords: Epilepsy/seizure, optic nerves, oculomotor nerves,Trochlear nerves, Vision disorders, retinal disorders. Results: Epilepsy attacks reduce the thickness of optic nerve ganglions and retinal nerve fibers. Epileptic seizures with damage to retinal nerves and more precisely optic nerve ganglia reduce Retinal Nerve Fiber Layer (RNFL), Ganglion Cell Layer (GCL). Some studies have stated that hypoplasia of the optic nerve, which is a symptom of focal non-convulsive status epilepticus, has been associated with any kinds of epilepsy. Finally, these propositions ended with the reduction of sensitivity to light in several articles, vision response is reduced in patients with persistent epilepsy. Conclusion: visual power decrease and serious retinal nerve damage can be expected from epileptic seizures, that change indicators same as nerve thickness and sensitivity to light.

show abstract

Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study

Cited by 3 publications

References 14 publications

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up

Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy

New dimension of epilepsy complications: A literature systematic review of visual and retinal disorders

Contact Info

Product

Resources

About